Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
⁃ For all :
• Patients of legal age (age ≥ 18 years)
• Subjects affiliated to or benefiting from a social security scheme
• Free, written and informed consent signed by the participant and the investigator
⁃ For MDS patients :
• Sampling at diagnosis for MDS patients (WHO 2016 criteria)
• Presence of ring sideroblasts on bone marrow smear
⁃ For MGUS patients :
⁃ \- Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria).